Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 331 AL 345

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R.

Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.

Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease

Rommer PS, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J.

Neurodegener Dis. 2016;16(3-4):284-9. doi: 10.1159/000441565. Epub 2015 Nov 21.

Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study

Boada M, Ramos-Fernández E, Guivernau B, Muñoz FJ, Costa M, Ortiz AM, Jorquera JI, Núñez L, Torres M, Páez A.

Neurologia. 2016 Sep;31(7):473-81. doi: 10.1016/j.nrl.2014.02.003. Epub 2014 Jul 9.

Factors Associated With Preferences for Institutionalized Care in Elderly Persons: Comparing Hypothetical Conditions of Permanent Disability and Alzheimer's Disease

Werner P, Segel-Karpas D.

J Appl Gerontol. 2016 Apr;35(4):444-64. doi: 10.1177/0733464814546041. Epub 2014 Sep 22.

Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies

Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, Tyagi N.

Mol Neurobiol. 2016 Jan;53(1):648-661. doi: 10.1007/s12035-014-9053-6. Epub 2014 Dec 17.

The Effectiveness of a Culturally Sensitive Cognitive Behavioral Group Intervention for Latino Alzheimer's Caregivers

Gonyea JG, López LM, Velásquez EH.

Gerontologist. 2016 Apr;56(2):292-302. doi: 10.1093/geront/gnu045. Epub 2014 May 22.

How does a woman with Alzheimer's disease make sense of becoming cared for?

Borley G, Sixsmith J, Church S.

Dementia (London). 2016 Nov;15(6):1405-1421. doi: 10.1177/1471301214561647. Epub 2014 Dec 3.

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease

Ji C, Xue GF, Li G, Li D, Hölscher C.

Rev Neurosci. 2016 Jan;27(1):61-70. doi: 10.1515/revneuro-2015-0021.

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

Szeto JY, Lewis SJ.

Curr Neuropharmacol. 2016;14(4):326-38. doi: 10.2174/1570159x14666151208112754.

Comorbidities Matter: A Call to Improve Care for Hospitalized Patients with Alzheimer's and Parkinson's Disease

DiBartolo MC.

J Gerontol Nurs. 2016 Feb;42(2):4-5. doi: 10.3928/00989134-20160113-01.

Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM.

Curr Top Med Chem. 2016;16(17):1910-5. doi: 10.2174/1568026616666160204121725.

Phage M13 for the treatment of Alzheimer and Parkinson disease

Messing J.

Gene. 2016 Jun 1;583(2):85-89. doi: 10.1016/j.gene.2016.02.005. Epub 2016 Feb 8.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21.

Clinical drug research in chronic central neurodegenerative disorders

Müller T, Foley P.

Expert Rev Neurother. 2016 May;16(5):497-504. doi: 10.1586/14737175.2016.1163220. Epub 2016 Mar 21.

Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches

Salahuddin P, Fatima MT, Abdelhameed AS, Nusrat S, Khan RH.

Eur J Med Chem. 2016 May 23;114:41-58. doi: 10.1016/j.ejmech.2016.02.065. Epub 2016 Mar 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias